Clinical Trial Update: A Study of MK-8527 in Human Immunodeficiency Type 1 Virus (HIV-1) Infected Participants (MK-8527-002) [Phase 1]

View source ↗

Summary

Phase 1 trial of MK-8527 in HIV-1 infected participants has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• MK-8527

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Human Immunodeficiency Virus, AIDS Virus | Phase 1 | Status: COMPLETED | Results posted: 2020-09-28